ondansetron has been researched along with sumatriptan in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 9 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Sussman, N | 1 |
| Giacovazzo, M; Martelletti, P; Rinaldi, C; Stirparo, G | 1 |
| Chambers, B; Fabinyi, G; Siderov, J; Zalcberg, J | 1 |
| Bye, A; Keene, ON; Lacey, LF; Pritchard, JF | 1 |
| Coupar, IM; Hemedah, M; Mitchelson, FJ | 1 |
| Shane, R | 1 |
| Dubayle, D; Menétrey, D; Servière, J | 1 |
| Andrews, PL; Cheng, FH; Moreaux, B; Ngan, MP; Rudd, JA; Sam, TS; Wai, MK; Wan, C | 1 |
| Cataldo, S; Chiodera, P; Coiro, V; Maffei, ML; Minelli, R; Vacca, P; Volpi, R; Volta, E | 1 |
2 review(s) available for ondansetron and sumatriptan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The potential benefits of serotonin receptor-specific agents.
Topics: Antidepressive Agents; Buspirone; Depressive Disorder; Humans; Isoxazoles; Ondansetron; Piperazines; Piperidines; Receptors, Serotonin; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin; Sumatriptan; Triazoles | 1994 |
19 other study(ies) available for ondansetron and sumatriptan
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Upregulated expression of peripheral serotonergic receptors in migraine and cluster headache by sumatriptan.
Topics: Adult; Analysis of Variance; Binding, Competitive; Cluster Headache; Ergotamine; Female; Flow Cytometry; Humans; Male; Migraine Disorders; Monocytes; Ondansetron; Receptors, Serotonin; Sumatriptan; Up-Regulation | 1994 |
Migraine following the use of a 5-hydroxytryptamine antagonist.
Topics: Ergotamine; Female; Humans; Middle Aged; Migraine Disorders; Oligodendroglioma; Ondansetron; Sumatriptan | 1993 |
Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed?
Topics: Bismuth; Body Fluid Compartments; Data Interpretation, Statistical; Humans; Normal Distribution; Ondansetron; Pharmacokinetics; Randomized Controlled Trials as Topic; Ranitidine; Sumatriptan | 1997 |
[3H]-Mesulergine labels 5-HT7 sites in rat brain and guinea-pig ileum but not rat jejunum.
Topics: 5-Methoxytryptamine; Animals; Binding Sites; Binding, Competitive; Brain; Dose-Response Relationship, Drug; Ergolines; Female; Free Radical Scavengers; Guinea Pigs; Ileum; In Vitro Techniques; Jejunum; Male; Muscle Contraction; Ondansetron; Radioligand Assay; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Spiro Compounds; Sulfonamides; Sumatriptan; Tritium | 1999 |
Development and implementation of practice guidelines (Part 1).
Topics: Acquired Immunodeficiency Syndrome; Colony-Stimulating Factors; Drug Utilization; Hospital Bed Capacity, 500 and over; Humans; Los Angeles; Migraine Disorders; Ondansetron; Pharmacy Service, Hospital; Practice Guidelines as Topic; Sumatriptan; Vomiting | 1994 |
Evidence for serotonin influencing the thalamic infiltration of mast cells in rat.
Topics: Animals; Cell Degranulation; Cell Movement; Diencephalon; Immunohistochemistry; Male; Mast Cells; Microscopy, Fluorescence, Multiphoton; Ondansetron; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Serotonin; Serotonin 5-HT1 Receptor Agonists; Sumatriptan; Thalamus | 2005 |
Evaluation of the anti-emetic potential of anti-migraine drugs to prevent resiniferatoxin-induced emesis in Suncus murinus (house musk shrew).
Topics: Animals; Antiemetics; Butanols; Capsaicin; Cyclooxygenase Inhibitors; Dihydroergotamine; Diphenhydramine; Diterpenes; Domperidone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Indomethacin; Malates; Methysergide; Metoclopramide; Migraine Disorders; Ondansetron; Piperidines; Ruthenium Red; Scopolamine; Serotonin Antagonists; Serotonin Receptor Agonists; Shrews; Sumatriptan; Time Factors; Tropanes; Vomiting | 2005 |
Effect of serotonergic system on AVP secretion induced by physical exercise.
Topics: Adult; Arginine Vasopressin; Blood Glucose; Buspirone; Exercise; Hemodynamics; Humans; Male; Ondansetron; Osmolar Concentration; Serotonin; Serotonin Receptor Agonists; Sumatriptan; Young Adult | 2010 |